ClearPoint Neuro, Inc. (CLPT) Earnings
ClearPoint Neuro, Inc. is expected to report next earnings on November 5, 2026 (in NaN days), with a consensus EPS estimate of $-0.31. CLPT has beaten EPS estimates in 3 of its last 12 reported quarters (average surprise -22.3% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 3, 2026 | $-0.29 | $-0.38 | -32.6% | $11M | -14.6% |
| May 13, 2026 | $-0.28 | $-0.32 | -14.3% | $12M | +1.3% |
| Mar 17, 2026 | $-0.20 | $-0.27 | -37.5% | $10M | +3.6% |
| Nov 6, 2025 | $-0.20 | $-0.21 | -5.0% | $9M | -14.8% |
| Feb 26, 2025 | $-0.15 | $-0.20 | -33.3% | $8M | -5.6% |
| Nov 7, 2024 | $-0.17 | $-0.18 | -5.9% | $8M | +4.4% |
| Mar 12, 2024 | $-0.22 | $-0.19 | +13.6% | $7M | +4.3% |
| Nov 9, 2023 | $-0.25 | $-0.20 | +20.0% | $6M | -9.3% |
| May 11, 2023 | $-0.18 | $-0.23 | -27.8% | $5M | +6.5% |
| Mar 1, 2023 | $-0.22 | $-0.18 | +18.2% | $5M | -0.5% |
| Aug 9, 2022 | $-0.18 | $-0.18 | +0.0% | $5M | +2.3% |
| Mar 1, 2022 | $-0.19 | $-0.19 | +0.0% | $4M | -0.4% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · August 3, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
### Long-Term Strategy and Prioritization Adjustment - ClearPoint's four-pillar long-term growth strategy remains unchanged, but the company has reallocated resources to three elevated, near-term priorities for H2 2026 in response to updated regulatory and market developments. - The company's core mission is to build a complete neuro ecosystem for minimally invasive cell and gene therapy delivery to the brain, addressing a large unmet medical need for neurological disorders. ### Accelerated Regulatory Progress and Commercial Readiness - Recent FDA updates indicate openness to accelerated trial designs for rare disease gene therapies, with multiple partner programs targeting BLA submissions as early as H2 2026, far faster than previously expected six months ago. - 60+ biopharma partner pipeline has seen widespread recent progress: Unicure gained accelerated approval pathway eligibility for AMT-130 (Huntington's) targeting a Q3 BLA submission; Aspen Neuroscience received RMAT designation for Parkinson's therapy; multiple other partners completed enrollment, presented positive data, or secured funding/regulatory alignment for their programs. - ClearPoint has reactivated its clinical support growth strategy to avoid being a bottleneck for partner launches, hiring and training a global clinical specialist team across the U.S., EU, Canada, and Japan to support phase 3 trials and future commercial launches. 10-15 trials using ClearPoint technology are expected to enroll patients in the next 18 months. ### ClearPoint Advanced Laboratories (CAL) Preclinical Facility Progress - As of July 2026, ClearPoint has taken possession of the 30,000 square foot CAL preclinical and analytical facility in Torrey Pines, California. - The company has signed its first GLP service statement of work, expected to be completed in H1 2027 when all equipment is fully installed and operational. - The new facility adds GLP capability, new in-house services (e.g. histology), and expanded capacity, enabling new revenue streams for the preclinical services business. The Q2 2026 revenue miss vs internal plans was due to delayed preclinical service ramp, but growth is expected to resume in H2 2026. ### Next-Generation Technology Development - ClearPoint announced a 10-year focused ultrasound drug delivery partnership, which when combined with its in-development robotic platform and Harmony 1.0 single-workflow control software, will support commercial scale, efficiency, and expansion after partner therapy approvals. - The robotic platform received positive feedback from over 50 neurosurgeons in Q2 2026; it is purpose-built for cranial procedures, filling an unmet need in busy cranial-focused operating rooms. - Fully functional preclinical prototypes are expected to be operational at the CAL facility in 2027, generating additional biologics and drug delivery service revenue.
Guidance
- 2026 full-year revenue guidance is revised to $48 million to $52 million, down from prior plans, as the company reallocates investment from traditional sales expansion to commercial readiness, global regulatory expansion, CAL facility capital expenditures, and next-generation technology (focused ultrasound, robotics, Harmony software) development. - Management expects operational cash burn to decrease in H2 2026 following completion of the ERIS integration. - For 2027, management expects total revenue growth in the high teens to 20% range, with upside potential from faster-than-expected ramp of GLP preclinical studies at the CAL facility and accelerated revenue from any 2027 commercial approvals of partner cell/gene therapies (including potential stocking orders from partners that would accelerate revenue recognition).
Segment performance
Total Q2 2026 revenue was $10.9 million, an 18% increase from $9.2 million in Q2 2025. 1. Biologics and drug delivery: Revenue decreased 15% year-over-year to $4.0 million, accounting for ~36.7% of total Q2 2026 revenue. The decrease was driven by a non-recurring $0.9 million customer order from Q2 2025, partially offset by a $0.2 million increase in service revenue. 2. Neurosurgery navigation therapy: Revenue grew to $5.6 million, accounting for ~51.4% of total Q2 2026 revenue. Growth was driven by Aeroflow product sales and the 3.0 operating room navigation software, which boosted procedural volumes. 3. Capital equipment and software: Revenue increased 24% year-over-year to $1.3 million, accounting for ~11.9% of total Q2 2026 revenue. Growth came from increased placements of Pierpoint navigation systems, PRISM laser units, and airflow control units.
Risks & headwinds
- Forward-looking statements (including launch timelines, revenue projections, and capacity scaling) are subject to risks that could cause actual results to differ materially, as referenced in the company's SEC filings. - Cash burn from new investments (clinical team expansion, CAL facility buildout, technology development) requires intentional prioritization of spending to maintain sufficient cash runway. - Preclinical service revenue ramp is dependent on partner comfort with the new facility, and a slower-than-expected ramp resulted in a Q2 2026 revenue miss vs internal projections. - Supply chain and geographic redundancy requests from partners require additional investment and operational planning to mitigate tariff, natural disaster, and acquisition-related supply risks.
Analyst Q&A
Q: What organizational changes came with the strategic reprioritization, and what is the expected 2027 growth outlook?
A: The adjustment is not a massive reorganization, but a shift in hiring focus to meet future B2B biopharma partnership demand rather than traditional device sales roles. Management expects 2027 total growth in the high teens to 20% range. Upside is possible from faster GLP study ramp at the new CAL facility (with equipment installation on track for Q1 2027) and accelerated revenue if a partner therapy gets approved in 2027, as partners may place large stocking orders to de-risk their launch. The first signed GLP statement of work is a multi-million dollar project, with full revenue recognition expected by H1 2027.
Q: How confident is management that ClearPoint can scale clinical capacity in time to avoid being a bottleneck for partner approvals, and what is the revenue opportunity for Unicure's AMT-130?
A: Management is very confident in scaling capacity: the company already has 30-40 trained clinical specialists, with new hires currently in training, enough to support thousands of cases annually. The company reallocated hiring away from traditional sales roles to cut unnecessary cash burn while expanding clinical support, and can accelerate hiring for Aeroflow if clinical trial results drive higher demand. For AMT-130, 15 U.S. centers have already committed to 50-100 total cases per week, and ClearPoint generates $15,000 to $25,000 in revenue per AMT-130 procedure, at the higher end of ClearPoint's $12,000 to $15,000 average per partner procedure.
Q: What incremental capacity and new services does the CAL facility add, and what is its long-term revenue potential?
A: The CAL facility adds growth across three vectors: expanded total capacity to run more and larger preclinical studies, new GLP compliance capability required for FDA submissions (which delivers larger, higher-margin studies than ClearPoint's previous non-GLP pilot work), and new in-house services such as histology that ClearPoint previously had to outsource. The old facility could support roughly $8 million in annual preclinical revenue, while the new CAL facility has potential to surpass $60 million in annual revenue from preclinical services, with just 1-2 large GLP studies able to meaningfully accelerate growth.
Q: Have commercial ASP negotiations begun for co-labeled products, and what is the pricing dynamic vs clinical trial pricing?
A: ClearPoint is currently in active commercial pricing and supply negotiations with multiple partners. Many partners request additional supply protections (such as regional redundant manufacturing or IP escrow arrangements to mitigate supply and acquisition risk), which ClearPoint provides in exchange for higher commercial ASPs. ASPs typically increase from bench testing to clinical trials to commercial launch; higher ASPs are generally easier to negotiate than royalties on partner drug sales, though royalty arrangements are sometimes reached. Co-labeling can include just the cannula or both the cannula and navigation system, depending on the partner and therapy.